Sana Biotechnology, Inc. (SANA)

9.08 +0.36 (+4.13%) At close: 04:00PM EDT

Sana Biotechnology, Inc.

188 East Blaine Street
Suite 400
Seattle, WA 98102
United States
206 701 7914
https://www.sana.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 328

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Steven D. Harr M.D.	President, CEO & Director	1.04M	N/A	1970
Ms. Robin Andrulevich	Executive VP & Chief People Officer	N/A	N/A	1966
Dr. Edward Rebar Ph.D.	Head of Cell Engineering	N/A	N/A	1968
Mr. Paul Brunetta M.D.	Senior VP and Head of Clinical & Translational Science	N/A	N/A	N/A
Mr. Christian Hordo M.B.A.	Executive VP & Chief Business Officer	485.03k	N/A	1983
Dr. Sonja Schrepfer M.D., Ph.D.	Senior VP & Head of Hypoimmune Platform	N/A	N/A	1975
Dr. Terry Fry M.D.	Senior VP & Head of T Cell Therapeutics	N/A	N/A	1967
Dr. Steven A. Goldman M.D., Ph.D.	Senior VP & Head of CNS Therapy	N/A	N/A	1958
Ms. Farah Anwar	Head of Development Operations & IDE Leader	N/A	N/A	N/A
Dr. Gary Meininger M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Corporate Governance

Sana Biotechnology, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.